• Craneware LSE:CRW fell24.89% on 21 September 2026, making it one of the largest decliners in the market snapshot.
Eden Research Plc LSE:EDEN came under renewed selling pressure on21 September 2026, falling9.52% to 1.90p. The move follows a volatile period for the shares, with the stock having closed at 2.10p on 18 September after gaining 5.00% during that session.
• The fall comes only days after the company released its H1 2026 results, giving investors fresh information about revenue, cash resources, costs and the pace of its commercial expansion.
• The company remains focused on the commercialisation of its patentedFruitflowtomato extract technology, which is used in food, beverage and dietary supplement applications.
• The decline occurred on the same day that Verici Dx announced the plannedQ4 2026 launch of TranscripTx, a new genetic test designed specifically for the transplant community.
AstraZeneca is one of the world's largest research-based pharmaceutical companies. Its portfolio spans oncology, rare disease and a biopharmaceuticals division that covers cardiovascular, renal and metabolic medicines alongside respiratory and immunology. The scale is now considerable. Total revenue reached $30.7bn in the six months …
Oxford Biomedica plc shares rose 1.97% today, based on the supplied market data. The move comes amid ongoing corporate activity, including a confirmed unsolicited cash offer from funds managed by EQT for the entire company, alongside continued strong underlying operational execution.
Syncona Limited shares rose 6.45% today, based on the supplied market data. The move comes as the life science investor continues to progress toward a series of clinical value-inflection points it has flagged for calendar year 2026.
The full-year results for the year to 31 March 2026 continued a run of expansion.Revenuerose 11% to £31.6m, adjusted EBITDA increased 28% to £2.6m, and the company ended the year with cash of £11.1m, proposing aDividendof 6.3p, according to its reporting. This marked a …
AstraZeneca is one of the world's largest research-based pharmaceutical companies. Its portfolio spans oncology, rare disease and a biopharmaceuticals division that covers cardiovascular, renal and metabolic medicines alongside respiratory and immunology. The scale is now considerable. Total revenue reached $30.7bn in the six months …